NCT05740670 is a NA clinical trial of Dr. Kellyann's Bone Broth in Weight Loss, sponsored by Veyl Ventures LLC.

Who is sponsoring NCT05740670?

NCT05740670 is sponsored by Veyl Ventures LLC.

What drugs are being tested in NCT05740670?

Interventions in NCT05740670: Dr. Kellyann's Bone Broth.

What condition does NCT05740670 study?

NCT05740670 studies Weight Loss.

Is NCT05740670 still recruiting?

NCT05740670 is currently completed. Last updated 30 January 2024.

Last reviewed 2024-01-30 · How we verify

NCT05740670

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety and Efficacy of a Bone Broth Diet on Weight Loss in Obese Adults

Completed NA Last updated 30 January 2024

What this trial tests

NA trial testing Dr. Kellyann's Bone Broth in Weight Loss in 100 participants. Completed in 10 October 2023.

Timeline

25 January 2023

Primary endpoint
10 October 2023

10 October 2023

Quick facts

Lead sponsor	Veyl Ventures LLC
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	25 January 2023
Primary completion	10 October 2023
Estimated completion	10 October 2023
Sites	1 location across Canada

Drugs / interventions tested

Dr. Kellyann's Bone Broth

Conditions studied

Weight Loss — all drugs for Weight Loss →

Sponsor

Veyl Ventures LLC

Who can join

Adults 35 to 65, any sex, with Weight Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to investigate the safety and efficacy of a bone broth diet on weight loss in obese adults. The change in weight and body mass index (BMI) following the bone broth diet will be measured from baseline at Days 22 and 50. Additionally, the safety and tolerability of the bone broth diet will be measured by the occurrence of post-emergent adverse events (AEs).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Weight Loss

Currently open trials in the same condition.

NCT06811324 — Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults · Phase 2 · recruiting
NCT07223983 — Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) · Phase 1 · recruiting
NCT07213466 — Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder · Phase 4 · recruiting
NCT06785064 — Optimizing an Extended Care Intervention to Promote Weight Loss Maintenance · NA · recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05740670 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Veyl Ventures LLC
Last refreshed: 30 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05740670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing